The Food and Drug Administration’s recent approval of new Alzheimer’s drugs sparked a flicker of hope for the millions affected by this devastating disease. But this progress casts a puzzling shadow.
The drugs come at a high cost for relatively limited benefits, offering only a brief respite in the pace of cognitive decline. This reality raises a question: Are we fixated on such marginally effective treatments at the expense of more promising preventive measures?
Let's start with the truth!
Support the Broken Science Initiative.
Subscribe today →
recent posts
Hormones, muscle, metabolic health, and what modern medicine often misses
Hormonal balance, menopause, metabolic health, breast screening, and women’s longevity
Inside Dave Feldman’s KetoCa study and the questions surrounding its data, analysis, and quality control
